## Emi Hifumi

## List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4848536/publications.pdf

Version: 2024-02-01

687363 752698 29 430 13 20 citations h-index g-index papers 29 29 29 201 docs citations citing authors all docs times ranked

#	Article	IF	CITATIONS
1	Finding and characterizing a catalytic antibody light chain, H34, capable of degrading the PD-1 molecule. RSC Chemical Biology, 2021, 2, 220-229.	4.1	7
2	A new algorithm to convert a normal antibody into the corresponding catalytic antibody. Science Advances, 2020, 6, eaay6441.	10.3	6
3	New technologies to introduce a catalytic function into antibodies: A unique human catalytic antibody light chain showing degradation of $\hat{l}^2$ -amyloid molecule along with the peptidase activity. FASEB BioAdvances, 2019, $1$ , 93-104.	2.4	8
4	The structural diversity and the biological meaning of antibody. FASEB Journal, 2018, 32, lb80.	0.5	0
5	A unique method for antibody to possess the catalytic function (3 rd report). FASEB Journal, 2018, 32, lb77.	0.5	O
6	Role of the constant region domain in the structural diversity of human antibody light chains. FASEB Journal, 2017, 31, 1668-1677.	0.5	9
7	A novel method of preparing the monoform structure of catalytic antibody light chain. FASEB Journal, 2016, 30, 895-908.	0.5	10
8	Detection of influenza virus by a biosensor based on the method combining electrochemiluminescence on binary SAMs modified Au electrode with an immunoliposome encapsulating Ru (II) complex. Analytical and Bioanalytical Chemistry, 2016, 408, 5963-5971.	3.7	20
9	Biochemical features and antiviral activity of a monomeric catalytic antibody lightâ€chain 23D4 against influenza A virus. FASEB Journal, 2015, 29, 2347-2358.	0.5	14
10	Biochemical Features of a Catalytic Antibody Light Chain, 22F6, Prepared from Human Lymphocytes. Journal of Biological Chemistry, 2013, 288, 19558-19568.	3.4	15
11	Highly efficient method of preparing human catalytic antibody light chains and their biological characteristics. FASEB Journal, 2012, 26, 1607-1615.	0.5	31
12	Biological features of human catalytic antibody light chains showing antiâ€cancer activity. FASEB Journal, 2012, 26, 611.1.	0.5	0
13	Catalytic and Biochemical Features of a Monoclonal Antibody Heavy Chain, JN1-2, Raised against a Synthetic Peptide with a Hemagglutinin Molecule of Influenza Virus. Journal of the American Chemical Society, 2011, 133, 15015-15024.	13.7	9
14	Immunological and catalytic features of InfAâ€15 mAb and the light chain raised against hemagglutinin molecule for Influenza virus A type. FASEB Journal, 2011, 25, 928.2.	0.5	0
15	Characteristic features of InfA-15 monoclonal antibody recognizing H1, H3, and H5 subtypes of hemagglutinin of influenza virus A type. Journal of Bioscience and Bioengineering, 2010, 109, 598-608.	2.2	6
16	Catalytic digestion of human tumor necrosis factorâ€Î± by antibody heavy chain. FEBS Journal, 2010, 277, 3823-3832.	4.7	17
17	Catalytic Features and Eradication Ability of Antibody Light-chain UA15-L against Helicobacter pylori. Journal of Biological Chemistry, 2008, 283, 899-907.	3.4	54
18	Rapid Detection of BSA Protein by Electrochemiluminescence Sensor Combining an Immunoliposome Which Encapsulates a Ru Complex. Electrochemistry, 2008, 76, 579-582.	1.4	4

#	Article	IF	CITATIONS
19	Effects of vaccination by a recombinant antigen ure B138 (a segment of the $\hat{l}^2$ -subunit of urease) against Helicobacter pylori infection. Journal of Medical Microbiology, 2007, 56, 847-853.	1.8	16
20	Specific degradation of H. pylori urease by a catalytic antibody light chain. FEBS Journal, 2005, 272, 4497-4505.	4.7	17
21	Super catalytic antibody and antigenase. Journal of Bioscience and Bioengineering, 2004, 97, 143-152.	2.2	20
22	Catalytic antibody light chain capable of cleaving a chemokine receptor CCR-5 peptide with a high reaction rate constant. Biotechnology and Bioengineering, 2004, 86, 217-225.	3.3	43
23	Improvement of catalytic antibody activity by protease processing. Biochemical and Biophysical Research Communications, 2004, 315, 612-616.	2.1	4
24	Catalytic features of monoclonal antibody i41SL1-2 subunits. Biotechnology and Bioengineering, 2003, 84, 485-493.	3.3	18
25	Endopeptidase character of monoclonal antibody i41-7 subunits. Immunology Letters, 2003, 86, 249-257.	2.5	17
26	Targeted destruction of the HIV-1 coat protein gp41 by a catalytic antibody light chain. Journal of Immunological Methods, 2002, 269, 283-298.	1.4	51
27	Removal of catalytic activity by EDTA from antibody light chain. BioMetals, 2000, 13, 289-294.	4.1	8
28	How and Why 41S-2 Antibody Subunits Acquire the Ability to Catalyze Decomposition of the Conserved Sequence of gp41 of HIV-1. Applied Biochemistry and Biotechnology, 2000, 83, 209-220.	2.9	23
29	Structural Diversity Problems and the Solving Method for Antibody Light Chains. , 0, , .		3